United Services Automobile Association lowered its stake in shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) by 6.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 33,763 shares of the biotechnology company’s stock after selling 2,155 shares during the period. United Services Automobile Association owned about 0.06% of Aimmune Therapeutics worth $808,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Carroll Financial Associates Inc. acquired a new position in shares of Aimmune Therapeutics during the 4th quarter worth approximately $28,000. Bank of Montreal Can lifted its holdings in Aimmune Therapeutics by 47.9% in the fourth quarter. Bank of Montreal Can now owns 1,516 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 491 shares during the last quarter. Advisor Group Inc. lifted its holdings in Aimmune Therapeutics by 84.6% in the fourth quarter. Advisor Group Inc. now owns 1,737 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 796 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Aimmune Therapeutics by 37.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,609 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 708 shares during the last quarter. Finally, Proficio Capital Partners LLC acquired a new position in Aimmune Therapeutics in the fourth quarter valued at approximately $96,000. Institutional investors and hedge funds own 73.85% of the company’s stock.
A number of research firms have commented on AIMT. BidaskClub cut Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, March 21st. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Aimmune Therapeutics in a research report on Thursday, April 11th. Wedbush reaffirmed a “buy” rating and set a $80.00 price objective on shares of Aimmune Therapeutics in a research report on Tuesday, February 26th. Zacks Investment Research raised Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 29th. Finally, ValuEngine lowered Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, February 4th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $47.13.
TRADEMARK VIOLATION WARNING: This report was originally reported by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/aimmune-therapeutics-inc-aimt-holdings-trimmed-by-united-services-automobile-association.html.
Aimmune Therapeutics Profile
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Featured Story: What is a stock buyback?
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.